Research and Markets: BioPharmaceutical Industry in China - 2012: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends,Opportunities & Challenges

Research and Markets has announced the addition of the "BioPharmaceutical Industry in China - An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges" report to their offering.

“BioPharmaceutical Industry in China - An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges”

The Chinese Pharmaceutical market is currently the third greatest pharma market globally, after the US and Japan, and in 2011 was worth $40 billion. Buy Floxin (Ofloxacin) pills online without prescription It is forecast to increase dramatically by 2015 and increase its dominance as a leading player in Asia. As the current third market leader it is predicted that the Chinese pharma market will be the main competitor of the US by 2020.
This report describes the current therapeutics that are propelling the biopharmaceutical market in China. It examines the current economic climate and how China compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, diabetes and vaccines are elucidated and analysed.
This study reveals market figures of the overall Chinese pharmaceutical market and sub-markets. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. The study also provides a comprehensive financial and product review of key players in the biopharmaceutical industry in China. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.
In summary, the Chinese biopharmaceutical market has huge opportunities for growth. This industry will significantly affect the international healthcare market and has enormous potential for investment.
This report tackles key concerns to the Chinese biopharmaceutical market such as:
- Lack of regulatory policy and legislation
- Reimbursement schemes and payers concerns
- Funding and government sponsorship issues
- International scepticism of Chinese safety and efficacy therapeutic profiles
Companies Mentioned
- Abbottt China
- AstraZeneca China
- AstraZeneca Products in China
- Boehringer Ingelheim China
- Eli Lilly China
- GlaxoSmithKline China
- Johnson & Johnson Medical China
- Merck China
- Novartis China
- Pfizer China
- Roche China
- Amoytop Biotech
- FusoGen Pharmaceuticals
- Shanghai Huaguan Biochip
- SiBiono GeneTech
- Sinovac Biotech

National Disability Institute and Acorda Therapeutics Launch Free Webinars on Financial Wellness for People with Multiple Sclerosis

National Disability Institute (NDI) and Acorda Therapeutics announced they will launch a free six-part webinar series on financial, tax and investment topics for people living with multiple sclerosis (MS), their families and care teams. The National Disability Institute’s Financial Wellness Series sponsored by Acorda Therapeutics will begin this September and be led by top experts in tax, money management, benefits, employment, Social Security and other areas of personal finance. Due to the program’s success last year, Acorda and NDI worked together to provide resources on a greater number of topics than last year’s four webinars. Buy Actigall (Ursodiol (Ursodeoxycholic)) pills online without prescription

“Our survey showed that whether people had an MS diagnosis early or later in life, there is a critical lack of information to help people with MS understand how to manage their money, plan for their financial futures, access favorable tax provisions, effectively utilize public benefits and keep working”

In 2011, NDI completed an online survey of 3,000 people living with MS. Sixty-seven percent of respondents reported that their financial positions declined after their MS diagnosis, while nearly 74 percent reported that they did not use financial planning programs or strategies to manage or stabilize their finances.
“Our survey showed that whether people had an MS diagnosis early or later in life, there is a critical lack of information to help people with MS understand how to manage their money, plan for their financial futures, access favorable tax provisions, effectively utilize public benefits and keep working,” said Michael Morris, National Disability Institute’s Executive Director. “But there are many easy-to-use financial strategies and programs that can help people with MS achieve these goals, and the experts who lead each webinar will show them how to take steps toward greater economic independence and self-sufficiency.”
The webinar series will include six free online programs, each beginning at 3pm ET and lasting 90 minutes:

• September 5, 2012 - Being Money Smart
• September 26, 2012 - Prolonging Work - Supports To Keep You On The Job
• October 17, 2012 - Social Security Disability Insurance – The Impact of Work on Benefits
• November 7, 2012 - Supplemental Security Income – The Impact of Work on Benefits
• November 28, 2012 - Favorable Tax Provisions for Individuals with Disabilities
• December 19, 2012 - Saving and Investing – For Workers and For Individuals on Public Benefits

Programs include presentations and an opportunity for participants to ask questions. In 2011, when National Disability Institute and Acorda sponsored the first series of webinars on financial topics for people living with MS, more than 1,200 participants registered. Due to the strong demand, NDI and Acorda have expanded the program to cover more topics of interest in 2012.
The series is part of National Disability Institute’s Real Economic Impact (REI) Tour, an eight-year movement of more than 850 organizations in 100 cities across America that has helped more than 1.5 million people with disabilities take steps out poverty through access to financial education, asset building programs and free volunteer income tax assistance generating more than $1.3 billion in tax refunds.
“We at Acorda are very pleased to be sponsoring this groundbreaking educational webinar series for people living with MS, who often face financial challenges related to their disability and lack information that can help them protect their financial futures,” said Ron Cohen, M.D., president and CEO of Acorda Therapeutics. “Acorda’s corporate mission is to improve the lives of people affected by neurological diseases. While our focus is on developing therapies, support for programs on overall wellness, including financial and other topics, is also an important part of fulfilling this mission.”
About National Disability Institute
National Disability Institute (NDI) is national non-profit organization dedicated to building a better economic future for people with disabilities. The first national organization committed exclusively to championing economic empowerment, financial education, asset development and financial stability for all persons with disabilities, National Disability Institute effects change through public education, policy development, training, technical assistance and innovative initiatives such as the Real Economic Impact (REI) Tour, which brings tax and financial education for people with disabilities to more than 100 cities nationwide. Since 2005, the REI Tour has helped more than 1.5 million people with disabilities receive more than $1.3 billion in tax refunds.
About Acorda Therapeutics
Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with MS, spinal cord injury and other neurological conditions.
Acorda markets AMPYRA^(R) (dalfampridine) Extended Release Tablets, 10 mg, in the United States as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is marketed outside the United States as FAMPYRA(R) (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda. AMPYRA and FAMPYRA are manufactured under license from Alkermes Pharma Ireland Limited.
The Company also markets ZANAFLEX CAPSULES^(R) (tizanidine hydrochloride) and ZANAFLEX^(R) (tizanidine hydrochloride) tablets, a short-acting drug for the management of spasticity. Acorda also receives sales royalties on tizanidine hydrochloride tablets, an authorized generic version of ZANAFLEX CAPSULES distributed by Watson Pharmaceutics, Inc. under its agreement with Acorda.
Acorda is developing an industry-leading pipeline of novel neurological therapies. The Company is studying AMPYRA to improve a range of functional impairments caused by MS, as well as its use in other neurological conditions, including cerebral palsy and chronic stroke. In addition, Acorda is developing clinical stage compounds AC105 for acute treatment of spinal cord injury and GGF2 for treatment of heart failure. GGF2 is also being investigated in preclinical studies as a treatment for neurological conditions such as stroke and spinal cord injury. Additional preclinical programs include rHIgM22, a remyelinating monoclonal antibody for the treatment of MS, and chondroitinase, an enzyme that encourages nerve plasticity in spinal cord injury

Ancestor Lucy Lived With Tree-Climbing Cousins

Researchers say a 3.4 million-year-old fossilized foot found in Ethiopia did not belong to a member of Australopithecus afarensis, the hominin species of our early upright-walking ancestor "Lucy", but to a tree-climbing hominin cousin with whom she and her relatives co-existed. They write about how they came to this conclusion in the 29 March online issue of Nature. Buy Oxsoralen tabs online without prescription

The fossil of the partial foot was found in 3.4-million-year-old rocks at Woranso-Mille in the Afar region of Ethiopia, where lead author Dr Yohannes Haile-Selassie, curator of physical anthropology at The Cleveland Museum of Natural History in the US, led the field research.

Bones of Australopithecus afarensis, have also been found in the area, which is known locally as Burtele.

Haile-Selassie and colleagues say the partial foot fossil, which was discovered in February 2009, indicates that more than one species of early human ancestor with different means of locomotion, one walking upright, and the other climbing trees, existed between 3 and 4 million years ago:

"The Burtele partial foot clearly shows that at 3.4 million years ago, Lucy's species, which walked upright on two legs, was not the only hominin species living in this region of Ethiopia," said Haile-Selassie in a statement.

"Her species co-existed with close relatives who were more adept at climbing trees, like 'Ardi's' species, Ardipithecus ramidus, which lived 4.4 million years ago," he added.

Lucy's big toe is aligned with the other four toes, for walking on two legs, like we do. But the Burtele foot apparently has an opposable big toe, like a thumb, allowing the foot to grasp branches. This is like the earlier Ardi, and similar to modern apes.

The researchers write in their paper that the opposing big toe "not only indicates the presence of more than one hominin species at the beginning of the Late Pliocene of eastern Africa, but also indicates the persistence of a species with Ar. ramidus- like locomotor adaptation into the Late Pliocene".

Haile-Selassie said other features of the Burtele foot show it did not belong to an ape, confirming that it is is truly a hominin, report Nature News, who also report that Daniel Lieberman, an anthropologist at Harvard University in Cambridge, Massachusetts, who was not involved in the study, agrees.

Lieberman said the Burtele foot is "very much like the Ardipithecus foot, which I believe had many hominin features, so it's likely to be a hominin".

Co-author and project co-leader Dr Bruce Latimer of Case Western Reserve University said they were shocked by the discovery. They had never seen bones like this before:

"While the grasping big toe could move from side to side, there was no expansion on top of the joint that would allow for expanded range of movement required for pushing off the ground for upright walking. This individual would have likely had a somewhat awkward gait when on the ground," he explained.

The researchers haven't been able to assign the Burtele foot to a species because there is no skull or dental elements to go with it.

The foot was found under a layer of sandstone and the researchers used a radioactive dating method called argon-argon to determine its age. The argon-argon method uses the ratio of radioactive potassium-40 in a sample of rock to the amount of its decay product, argon-40, to work out the age of the rock, which in this case was found to be 3.46 million years.

Co-author Dr Beverly Saylor, also of Case Western Reserve University, said nearby fossils of fish, crocodiles and turtles, as well as the physical and chemical properties of the sediments, indicate the surrounding area was once a "mosaic of river and delta channels adjacent to an open woodland of trees and bushes".

"This fits with the fossil, which strongly indicates a hominin adapted to living in trees, at the same time 'Lucy' was living on land," she added.

The finding adds weight to the idea that human evolution is not a simple linear progression from apes but a more complex affair.